The vaccine manufacturer has an additional 195 million 30-, 10- and 3-microgram doses in a stockpile the U.S. can also purchase.
Pending approval and authorization from the FDA and CDC, the summer delivery could include updated vaccines that are more effective against omicron, BioNTech’s chief business and chief commercial officer, Sean Marett, said in the press release. An FDA panel recently recommended omicron-targeted vaccines June 28, with future meetings planned for July.
In another move, Pfizer submitted a New Drug Application to the FDA June 30 with the hopes of prescribing Paxlovid to people with severe illness from COVID-19. The antiviral treatment is currently only authorized for people with mild to moderate symptoms.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
